Cumberland Pharmaceuticals and Gloria Pharmaceuticals Announce R&D Investment - - BioPharm International

ADVERTISEMENT

Cumberland Pharmaceuticals and Gloria Pharmaceuticals Announce R&D Investment



Cumberland Pharmaceuticals and Gloria Pharmaceuticals reported a joint R&D initiative. Each company has made a $1 million investment in Cumberland Emerging Technologies (CET), which is majority owned by Cumberland and partners with academic research centers to develop biopharmaceutical technologies. The new funds will be used to accelerate development of CET's pipeline of new product candidates from Vanderbilt University and other regional research centers.

CET was established by Cumberland Pharmaceuticals, Vanderbilt University, and the state of Tennessee to support the development of biopharmaceutical product candidates. Gloria will have the first opportunity to negotiate a license to CET products for China, and Cumberland will retain access to CET's product rights for the rest of the world.

Source: Cumberland Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here